Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introduction Cognitively impaired patients with negative biomarkers of amyloidosis but with neurochemical evidence of Tau pathophysiology or neurodegeneration or both are classified as "suspected non-Alzheimer pathophysiology" (SNAP), according to the 2018 research framework for a biological definition of Alzheimer's disease (AD). The SNAP concept remains incompletely characterized, and associations of amyloid and tau biomarkers with survival outcomes in the SNAP context remain unclear. Methods We conducted a retrospective study in patients with a SNAP biomarker constellation, recruited from two tertiary centers between 2019 and 2024.

What this study adds

Evidence grade: Low

The record lists 99 participants. This retrospective study looked at survival outcomes in patients classified as having suspected non-Alzheimer pathophysiology, based on negative amyloid biomarkers with evidence of tau pathophysiology or neurodegeneration. Reported effect size: AUC = 0.83; AUC = 0.82.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Briel, N., Borsi, M., Schreiner, S. J., Schneider, T., Loosli, S. V., Togni, C., et al. (2026). Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology. Journal of neurology. https://doi.org/10.1007/s00415-026-13841-x

Vancouver

Briel N, Borsi M, Schreiner SJ, Schneider T, Loosli SV, Togni C, et al. Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology. Journal of neurology. 2026. doi:10.1007/s00415-026-13841-x. PMID: 42060129.

BibTeX

@article{briel2026-42060129,
  author  = {Briel, N. and Borsi, M. and Schreiner, S. J. and Schneider, T. and Loosli, S. V. and Togni, C. and Carta, M. C. and Loosli, J. and others},
  title   = {{Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology}},
  journal = {Journal of neurology},
  year    = {2026},
  doi     = {10.1007/s00415-026-13841-x},
  pmid    = {42060129},
  url     = {https://doi.org/10.1007/s00415-026-13841-x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This retrospective study looked at survival outcomes in patients classified as having suspected non-Alzheimer pathophysiology, based on negative amyloid biomarkers with evidence of tau pathophysiology or neurodegeneration. It is about characterizing this group and its outcomes, not about any treatment, cure or prevention.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 1 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 40 of the 96 points it could be judged on, which is 42 of 100. Total 42 of 100.40 of the 96 points we could judge = 42 of 100

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 40 of the 96 points we could judge it on, which is 42 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of neurology)
Journal's citation record 2 / 4 Journal of Neurology: journal h-index 208 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 1 / 4 99 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Hans H Jung holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record 3 / 3 Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 12 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42060129)
Free to read 0 / 2 Behind a paywall — scores zero
Points 40 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 96 points we could judge it on is 42 out of 100.
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →